Commencez
ChristopherCarrollSmith

ABBV remains a strong investment even after its recent run

Long
AbbVie Inc. (NYSE:ABBV)  
ChristopherCarrollSmith Mis à jour   
NYSE:ABBV   AbbVie Inc.
Trend Lines Fundamental Analysis pharmaceuticals biotech Earnings
18
0
trendline fundamental pharmaceuticals biotech earnings
Abbvie has been surging lately after a bullish trend line break, but it remains undervalued at the current price. The analyst summary score for Abbvie is 9.6/10, and the average analyst price target is $92 per share. Personally, I think Abbvie's strong earnings forecast and 5.5% dividend yield justifies $100 per share. Call volume in Abbvie is very bullish today after its cancer drug Imbruvica beat a rival cancer drug in a clinical trial.
Commentaire:
Abbvie may bounce from 50 RSI on the daily. Look for a green close today to enter. With a 5.3% dividend and a forward P/E under 10, I daresay the run isn't over yet.

snapshot

Idées en relation

ChristopherCarrollSmith
ABBV buy the dip ahead of pharma season
ChristopherCarrollSmith
ABBV should soon find support for a bounce
Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.